Clinical Trial Update: Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial of oral PHA-848125AC in thymic carcinoma was terminated. The results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Drugs mentioned

• PHA-848125AC

Snippet

Sponsor: Tiziana Life Sciences LTD | Conditions: Thymic Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2018-10-16